Adezunap

Vertebral Column Disorder

Apurano Pharmaceuticals GmbHUNKNOWNPhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 89/ 100

Competitive context

9 Active assets in the Vertebral Column Disorder cohort.

Asset / Sponsor	Phase	Rating
Oxycodone Grünenthal GmbH	Phase 4	BBB
Dinitrogen Monoxide Medical College of Wisconsin	Phase 4	BB
NEPENTHE MedtronicNeuro	Phase 4	BB
Glycopyrrolate Medical College of Wisconsin	Phase 4	BB
Dexmedetomidine Medical College of Wisconsin	Phase 4	BB

View all 39 →

Same molecule, other indications

Adezunap is also rated in:

diabetic neuropathyActive

B

Indicative · Phase 3

60 / 100

diabetic polyneuropathyActive

B

Indicative · Phase 3

60 / 100

peripheral nervous system disorderActive

B

Indicative · Phase 3

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.